financetom
Business
financetom
/
Business
/
BCE Q1 Estimates Lowered at UBS
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BCE Q1 Estimates Lowered at UBS
Apr 4, 2024 10:47 AM

01:16 PM EDT, 04/04/2024 (MT Newswires) -- UBS is lowering its estimates for BCE Q1 2024 revenues/EBITDA by 2-3% to reflect higher competition, lower ARPU and tough comps in Media.

Wireless industry tailwinds are expected to continue to drive strong loadings while elevated competition results in higher churn (UBSe +20 bps yoy; +10 bps prior), driving 38K postpaid net adds. UBS expects ARPU to decline 0.6% yoy, and to continue to fall through the year. Along with lower product revenues, wireless revenue growth is forecast to slow to 3.3%, from 3.7% in Q4 and 6.3% a year ago.

In wireline, KPIs are expected to be solid with 32K broadband adds (vs. +27K a year ago), inc.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Grayscale CEO sees bitcoin ETF outflows reaching equilibrium
Grayscale CEO sees bitcoin ETF outflows reaching equilibrium
Apr 10, 2024
(Reuters) - Outflows from the Grayscale Bitcoin Trust ( GBTC ) may be reaching an equilibrium after months of investor selling, Michael Sonnenshein, CEO of crypto asset manager Grayscale Investments, told Reuters on the latest episode of Inside ETFs. Grayscale has battled to retain dominance of the bitcoin exchange-traded fund (ETF) market since rival offerings from nine other issuers emerged...
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept
Apr 10, 2024
05:13 AM EDT, 04/10/2024 (MT Newswires) -- ALX Oncology Holdings ( ALXO ) said Tuesday that data from the ongoing phase 1/2 trial of evorpacept, in combination with standard rituximab and lenalidomide, in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated the combination's promising initial activity. The company said the clinical trial enrolled 20 patients, with...
Porsche reports 4% fall in Q1 deliveries
Porsche reports 4% fall in Q1 deliveries
Apr 10, 2024
(Reuters) - Stuttgart-based sportscar maker Porsche delivered 4% fewer vehicles globally in the first quarter of 2024 compared to 2023, it said on Wednesday, citing a challenging market in China and customs-related delivery delays in North America. Global deliveries stood at 77,640 cars worldwide, Porsche said, with deliveries down 24% and 23% year-on-year in China and North America, respectively. In...
Volkswagen Q1 deliveries up
Volkswagen Q1 deliveries up
Apr 10, 2024
(Reuters) - German carmaker Volkswagen saw a slight rise in vehicle deliveries during the first three months of the year, as it recorded a growth in China as well as North and South America Volkswagen delivered a total 2.10 million vehicles during the first quarter, representing a 3.1% rise compared to the same time period last year. (Reporting by Tristan...
Copyright 2023-2026 - www.financetom.com All Rights Reserved